The role of Fc γ receptors in murine autoimmune thrombocytopenia

Markus Biburger, Susanne Aschermann, Anja Lux, Falk Nimmerjahn

► To cite this version:

Markus Biburger, Susanne Aschermann, Anja Lux, Falk Nimmerjahn. The role of Fc γ receptors in murine autoimmune thrombocytopenia. *Annals of Hematology*, 2010, 89 (s1), pp.25-30. 10.1007/s00277-010-0915-3 . hal-00535126

HAL Id: hal-00535126

<https://hal.science/hal-00535126>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The role of Fcγ receptors in murine autoimmune thrombocytopenia

Markus Biburger · Susanne Aschermann · Anja Lux · Falk Nimmerjahn

Received: 28 July 2009 / Accepted: 29 January 2010 / Published online: 24 February 2010
© Springer-Verlag 2010

Abstract Immune thrombocytopenia (ITP) can become a life-threatening condition that requires immediate medical attention. The loss in platelet numbers during ITP can be induced by a variety of triggers. Anti-platelet antibodies of several isotypes and subclasses are a major cause for ITP and are a hallmark of many complex autoimmune diseases such as systemic lupus erythematosus. Mouse models have been important to understand the effector pathways involved in antibody-mediated platelet depletion. Therapeutic interventions based on these results have been proven successful in treating human ITP, thus validating the use of these model systems. One major problem that remains to be answered is which cell populations are crucial for platelet removal. Targeting these cells directly might be a novel therapeutic strategy and will also be important to understand the underlying biological mechanisms.

Keywords Autoimmunity · ITP · Immunoglobulin G · Inflammation · Fc receptors

Introduction

Per year, roughly 0.05% to 0.1% of the population are estimated to develop immune thrombocytopenia (ITP) in the USA and Europe [1, 2]. Half of these cases occur in children, where in the majority of cases, ITP is transient and resolves spontaneously after several months. Therefore, there is no urgent need for treatment, and observing platelet

counts on a regular basis is usually sufficient. In adults, however, ITP often becomes chronic and requires medical intervention [2, 3]. Depending on the magnitude of platelet reduction, several mild to life-threatening symptoms, including bleeding at cutaneous, gingival, intracranial, and internal sites, can occur. It is accepted that platelet-specific antibodies of the immunoglobulin (IgG) isotype are a major cause for immune-mediated platelet depletion. Platelet-associated IgG can be detected in approximately 50–70% of the patients with ITP, and more than 50% of newborn children of mothers with ITP will have a transient thrombocytopenia due to the transfer of IgG through the placenta [1, 4, 5]. Similarly, infusion of serum from thrombocytopenic patients induced rapid platelet depletion in healthy volunteers [6]. Moreover, strategies aiming at depletion of autoantibody-producing B cells such as depletion with monoclonal antibodies (e.g., rituximab) or splenectomy are means to interfere with platelet depletion [3, 7]. It is still unclear what triggers the generation of platelet-specific IgG. As ITP can coincide with certain infections, one possibility might be the generation of cross-reactive antibodies during a pathogen-specific immune response recognizing platelet antigens [8]. The dominant target structures detected by murine and human platelet-specific IgG are glycoproteins (GP) such as GPIb, GPIIb, GPIIIa, or complexes thereof [3, 9–12]. Very similar targets are recognized by murine platelet-specific autoantibodies arising in a variety of autoimmune-prone mouse strains such as BXSB mice or BXSB/NZW F1 offspring [13]. Electron microscopy studies in human ITP patients have demonstrated that platelets can be taken up by monocytes, and injection of radio-labeled platelets showed that the major sites where platelets redistribute to after autoantibody injection are the spleen, the liver, and the lung [3, 14–17]. These results led to the conclusion that the reticulo-

M. Biburger · S. Aschermann · A. Lux · F. Nimmerjahn (✉)
Laboratory for Experimental Immunology and Immunotherapy,
Nikolaus-Fiebiger-Centre for Molecular Medicine,
Medical Department III, University of Erlangen-Nuremberg,
Glückstr. 6, 91054 Erlangen, Germany
e-mail: fnimmerj@molmed.uni-erlangen.de

endothelial system is the major site for autoantibody-mediated platelet removal. The cells of this system are of hematopoietic and non-hematopoietic origins and express receptors specific for the immunoglobulin G (IgG) Fc fragment. Cross-linking of Fc γ receptors (Fc γ R) by IgG-coated platelets results in the phagocytosis of these immune complexes and their removal from the circulation [18]. Other mechanisms that are discussed in the literature are complement-mediated lysis of platelets and the involvement of cytotoxic T cells [1, 19]. While all these observations imply some role for these different effector pathways and organs, they cannot distinguish between the importance of the individual pathways for the observed platelet depletion in patients. Thus, further studies in animal models are of major importance to decipher the role of the different effector mechanisms and to develop novel therapeutic concepts. This review will discuss some of the recent insights that have been gained with respect to effector mechanisms leading to platelet depletion in mice and how this knowledge might translate to novel strategies for therapy.

Immunoglobulin G-mediated effector pathways

As has been discussed for humans, mainly two effector pathways were suspected to be important for IgG-mediated platelet removal in mice. Both of these pathways are dependent on the antibody constant domain, which in the case of IgG can bind to cell surface receptors on innate immune effector cells (Fc γ R) or activate the complement pathway [18, 20, 21]. Fc γ Rs are widely expressed on cells of the innate (e.g., monocytes, mast cells, neutrophils, NK cells) and adaptive (B cells) immune system. In addition, Fc γ R expression has been demonstrated on dendritic cells and non-hematopoietic tissues such as endothelial and neuronal cells. Depending on the cell type, cross-linking of these receptors results in a variety of effector functions including antibody-dependent cell-mediated cytotoxicity, phagocytosis, release of pro-inflammatory mediators, or IgG-mediated feedback inhibition of B cells [18, 22]. The family of murine and human Fc γ Rs consists of several members that can be distinguished by two different means. First, by the affinity of the individual receptors for the different IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3 in mice) (Fig. 1). Fc γ RI (CD64) is the only receptor which can bind to monomeric IgG, whereas all the other receptors can bind IgG only in the form of immune complexes (IC). In general, the higher the affinity of the individual receptor, the narrower its specificity. Thus, Fc γ RI selectively binds to IgG2a with high affinity, Fc γ RIV binds IgG2a and IgG2b with intermediate affinity and Fc γ RIIB and Fc γ RIII bind IgG1, IgG2a, and IgG2b with low affinity [23]. This *in vitro* binding pattern reflects the importance of the individual Fc γ Rs for the activity of the individual IgG

subclasses in different *in vivo* model systems. Thus, IgG1 is essentially dependent on Fc γ RIII, whereas IgG2a and IgG2b are additionally dependent on Fc γ RI and Fc γ RIV [24–31]. The second distinguishing feature within the family of Fc γ Rs is whether they transduce activating or inhibitory signals. There is one inhibitory Fc γ R, Fc γ RIIB that shows a broad expression pattern on hematopoietic and non-hematopoietic tissues [32, 33]. In contrast, Fc γ RI, Fc γ RIII, and Fc γ RIV are activating receptors which have a more restricted cell type expression pattern. None of the activating receptors can signal autonomously but has to associate with signaling adaptor molecules such as the FcR common γ chain (γ chain). On cell types such as monocytes, macrophages, and neutrophils, activating Fc γ Rs are coexpressed with the inhibitory Fc γ RIIB [34]. Thus, Fc γ Rs set a threshold for cell activation as ICs will trigger both activating and inhibitory signaling pathways. The affinity of the individual IgG subclasses to the respective activating and the inhibitory Fc γ RIIB will determine antibody activity. Pro-inflammatory mediators, such as TNF- α , IFN- γ , or C5a, modulate IgG subclass activity by changing the ratio of activating to inhibitory Fc γ R expression [23, 35]. In addition to the differential binding of the individual IgG subclasses to Fc γ Rs, there is a differential capacity to activate the complement pathway. Whereas IgG1 is very inefficient in triggering the classical pathway of complement activation by binding to C1q, the other three IgG subclasses can do so efficiently. Therefore, it was suggested that the activity of IgG2a and IgG2b might be dependent on both, cellular Fc γ Rs and the complement pathway.

Effector pathways involved in murine ITP

Several platelet-specific monoclonal antibodies or polyclonal sera specific for mouse platelets can be used to induce ITP [29, 36–41]. One common antibody is the CD41-specific rat IgG1 clone MWReg30. As rat IgG1 is very similar to mouse IgG1, it is not efficient in activating mouse complement and can only bind to mouse Fc γ RIIB and Fc γ RIII. Consistent with these features, using either a blocking antibody for mouse Fc γ RIII or the Fc γ RIII knockout mouse completely prevented MWReg-induced platelet depletion [37, 40]. Similarly, a mouse IgG1 subclass switch variant derived from the platelet-specific mouse antibody clone 6A6 generated from (NZW $\times$ BSXB) F1 animals was completely dependent on Fc γ RIII [29]. More importantly, 6A6–IgG2a and IgG2b subclass variants were also fully dependent on cellular Fc γ Rs for their activity despite their capacity to activate the complement pathway. Consistent with this observation, an IgG3 subclass variant, which does not bind to any of the known Fc γ Rs with significant affinity but activates the complement pathway, did not lead to significant platelet depletion [29].

Fig. 1 Antibody Fcγ receptor interactions. Shown is the family of FcγRs in mice and their interactions with immunoglobulin G subclasses. The principal distinguishing feature between the family members is the differential affinity for IgG subclasses, the specificity

for a certain subclass, and the signal that they transduce. *ITIM* immunoreceptor tyrosine-based inhibitory motif, *ITAM* immunoreceptor tyrosine-based activation motif, *IC* immune complex

These results led to the conclusion that the complement system did not seem to be a major player for IgG-mediated platelet depletion in mice. Interestingly, a novel pathway resulting in a complement component C3-independent generation of C5a has been shown to be important for murine autoimmune hemolytic anemia induced by injection of red blood cell-specific IgGs [19, 35]. Although the details of this novel pathway are not entirely clear, it was suggested that C5a could be generated in an FcγR-dependent fashion and act as a pro-inflammatory mediator changing the ratio of activating to inhibitory FcγR expression towards a higher level of activating FcγRs. Using either C5a receptor-deficient mice or biological inhibitors of C5a should answer whether this pathway is involved in murine ITP as well and whether this might be a promising novel therapeutic approach for human ITP. Another interesting observation was made with respect to the level of involvement of individual activating FcγRs for IgG2a and IgG2b-mediated platelet clearance. In contrast to the capacity of IgG2a to bind to the high affinity FcγRI, mice with a deletion of this receptor did not have altered rates of IgG2a mediated platelet clearance [29]. In contrast, blocking antibodies for the medium affinity receptor FcγRIV resulted in an impaired platelet clearance. Similar results were obtained in human ITP patients where blocking antibodies to FcγRIIIA, which is the human ortholog of murine FcγRIV [23, 42], but not to human FcγRI were very efficient in blocking platelet depletion [43–46]. Thus, FcγRs are instrumental for IgG-mediated platelet depletion for murine and human ITP and are an attractive target for therapeutic intervention. Indeed, the injection of anti-D antibodies directed against red blood cells is an efficient means to block ITP by generating immune complexes that will compete for binding to activating FcγRs on innate immune effector cells. A problem arising with the use of FcγRIIIA-blocking antibodies in human therapy is the

induction of severe neutropenia due to cross-reactivity of the therapeutic antibody with human FcγRIIIB expressed on neutrophils, thereby targeting them for attack via antibody-dependent cellular cytotoxicity. The use of antibody variants with a mutated Fc fragment or F(ab)2 fragments might reduce this unwanted side effect. Recent evidence suggests that a long known therapy for ITP, the intravenous infusion of high doses of immunoglobulin G molecules pooled from thousands of donors (IVIg therapy), might mediate its anti-inflammatory activity by upregulating the inhibitory FcγRIIIB in mice and humans, thereby changing the threshold for innate immune effector cell activation [47, 48].

Effector cells and organs involved in murine (and human) ITP

As we now have a fairly complete picture of the molecular mechanisms responsible for IgG subclass-dependent platelet depletion, the crucial next question is which cell types express these receptors and where they are located (Fig. 2). Although this sounds trivial at first glance, we are only at the beginning to define the great variety of cell subpopulations in the myeloid lineage for example [49]. In humans, removal of the spleen is one option to stabilize platelet counts. In general, however, only 60–70% of the patients respond to this therapy, and in many cases, this does not lead to a full recovery of platelet numbers but rather stabilizes them on an acceptable level [2, 3]. Similar results have been obtained with autoimmune-prone mouse strains that develop anti-platelet antibodies spontaneously [50]. Of note, removal of the spleen also depletes a considerable number of autoantibody-producing plasma cells and plasma blasts. It is hard to evaluate therefore to what extent removal of splenic phagocytic cells contributes to the overall therapeutic effect. Thus, it is a safe assumption that

Fig. 2 The hunters and the prey. Shown are the effector cells and organs, which could be involved in autoantibody-mediated platelet depletion in ITP. In the blood, several cell types such as eosinophils, neutrophils, and monocyte subpopulations might be involved in platelet phagocytosis. In organs such as the lungs, the spleen, and the liver, tissue-resident macrophages are prime candidates as responsible effector cells. Besides cells of the hematopoietic system, non-hematopoietic cells such as endothelial cells express FcγRs and might phagocytose platelet-containing immune complexes

other organs or cell populations outside the spleen are involved in platelet removal. Interestingly, there seems to be an age-dependent involvement of different organs. During early age, splenectomy leads to better clinical responses than later in life [3]. Besides the spleen, the liver was suggested to be involved in removal of antibody-bound platelets. Using radioactively labeled platelets, it has been shown that a proportion of the injected radioactivity ends up in the liver after 24 h [16, 17]. While this is interesting, it does not exclude that cells after having taken up antibody-coated platelets migrate to the liver subsequently. In fact, injection of anti-platelet antibodies leads to a maximum of platelet depletion within 1 to 4 h in mice and humans [6, 29]. As further studies cannot be done in humans, murine model systems are required. The problem here is that a lot of crucial information regarding the mechanism and players involved in IgG-mediated effects have only been identified recently and are still under investigation. For example, the mouse ortholog to human FcγRIIIA has only been identified 4 years ago and is still not fully characterized [42, 51]. More importantly, monoclonal antibodies specific for all mouse-activating FcγRs have become available only recently. Therefore, there are still many open questions with respect to the exact FcγR expression pattern on individual cell types. In the blood, FcγRIII (important for IgG1-mediated platelet depletion)

and FcγRIV (important for IgG2a/IgG2b-mediated platelet depletion) are largely expressed on monocytes and neutrophils [18, 42]. NK cells, mast cells, eosinophils, and dendritic cells on the other hand largely lack expression of FcγRIV but do express FcγRIII. Besides the blood, most other organs such as the spleen, the liver, the lung, and the kidney contain cell types expressing different FcγRs. One of the dominant sources of FcγR expression in these organs are tissue-specific resident macrophages and endothelial cells. In the liver for example, Kupffer cells seem to express activating FcγRs in the spleen, red pulp macrophages are highly positive for FcγRs and thus could be involved in antibody-mediated platelet depletion [30]. In addition, strong FcγR expression can be detected on endothelial cells, although here, the dominant receptor seems to be the inhibitory FcγRIIB and probably FcγRIII to some degree. Therefore, either tissue-resident macrophages or blood monocytes and neutrophils could be involved in IgG2a/IgG2b-mediated platelet depletion, whereas IgG1-mediated platelet depletion could be triggered by other cell types as well. One of the cell types that can be excluded are NK cells as they do neither express FcγRIV nor co-express the inhibitory FcγRIIB, which regulates the activity of all IgG subclasses in mice [18]. Ideally mice with cell type-specific deletions of individual activating FcγRs would be required to come to definitive conclusions. Until these animals

become available, surrogate systems need to be used. Liposomes containing cytotoxic substances result in the specific depletion of monocytes and macrophages in the blood and in tissues such as the lung, the liver, and the spleen [52]. Indeed, liposome-treated mice showed an impaired platelet clearance mediated by a polyclonal rabbit anti-mouse platelet serum suggesting that monocytes and macrophages are involved in this process. As there are many different subpopulations of monocytes and macrophages, it is unclear which of these are important [49]. In addition, tissue macrophages are sometimes involved in maintenance of tissue organization, and depletion of spleen macrophages often leads to secondary rearrangements in structure, which might be important for antibody-mediated platelet depletion. One step closer to the human system, mice transgenic for human FcγRs have been developed and will be useful to study the impact of human FcγRs in a mouse model in vivo [53].

Conclusion and outlook

Taken together, recent studies have shed some light on the molecular pathways involved in immunoglobulin G-mediated platelet depletion. Despite the efficient activation of the complement pathway by the most active IgG subclasses, it seems clear that this does not directly contribute to platelet removal but may serve as an enhancing mechanism to modulate activating and inhibitory FcγR expression. In contrast, studies in humans and mice clearly indicate the importance of cellular FcγRs for platelet removal. As there are many different cell types that express the relevant FcγRs, it is unclear which of these contribute to platelet depletion. In addition, many of these cell populations are located in a variety of tissues and organs and thus are difficult to analyze. Although splenic cell populations seem to be involved in antibody-mediated platelet removal, it seems clear that alternative pathways independent of the spleen must exist and need to be characterized in detail to gain a deeper insight into the biology and pathomechanism of ITP.

Acknowledgment This work was supported by grants from the Bavarian Genome Research Network (BayGene) and the German Research Foundation (SFB 643 and FOR832).

References

1. Psaila B, Bussel JB (2007) Immune thrombocytopenic purpura. *Hematol Oncol Clin North Am* 21:743–759, vii
2. Cines DB, McMillan R (2005) Management of adult idiopathic thrombocytopenic purpura. *Annu Rev Med* 56:425–442
3. Karpatkin S (1997) Autoimmune (idiopathic) thrombocytopenic purpura. *Lancet* 349:1531–1536
4. Epstein RD, Lozner EL, Cobbe TS Jr, Davidson CS (1950) Congenial thrombocytopenic purpura; purpura hemorrhagica in pregnancy and in the newborn. *Am J Med* 9:44–56
5. Karpatkin S, Strick N, Karpatkin MB, Siskind GW (1972) Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders. *Am J Med* 52:776–785
6. Sprague CC, Harrington WJ, Lange RD, Shapleigh JB (1952) Platelet transfusions and the pathogenesis of idiopathic thrombocytopenic purpura. *J Am Med Assoc* 150:1193–1198
7. Garvey B (2008) Rituximab in the treatment of autoimmune haematological disorders. *Br J Haematol* 141:149–169
8. Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. *Blood* 113:6511–6521
9. Beardsley DS, Spiegel JE, Jacobs MM, Handin RI, Lux SE (1984) Platelet membrane glycoprotein IIIa contains target antigens that bind anti-platelet antibodies in immune thrombocytopenias. *J Clin Invest* 74:1701–1707
10. Fujisawa K, Tani P, McMillan R (1993) Platelet-associated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens. *Blood* 81:1284–1289
11. McMillan R (2000) Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. *Semin Hematol* 37:239–248
12. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE (1982) Specificity of autoantibodies in autoimmune thrombocytopenia. *Blood* 59:23–26
13. Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA (1993) Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice. *Blood* 82:837–844
14. Coetzee LM, Pieters H, van Wyk V, Cooper S, Roodt J, De Reys S, Badenhorst PN (2000) The effect of monoclonal anti-human-platelet antibodies on platelet kinetics in a baboon model: IgG subclass dependency. *Thromb Haemost* 83:148–156
15. Heyns AD, Lotter MG, Badenhorst PN, van Reenen OR, Pieters H, Minnaar PC, Retief FP (1980) Kinetics, distribution and sites of destruction of 111indium-labelled human platelets. *Br J Haematol* 44:269–280
16. Schmidt KG, Rasmussen JW (1985) Kinetics and distribution in vivo of 111In-labelled autologous platelets in idiopathic thrombocytopenic purpura. *Scand J Haematol* 34:47–56
17. Stratton JR, Ballem PJ, Gernsheimer T, Cerqueira M, Slichter SJ (1989) Platelet destruction in autoimmune thrombocytopenic purpura: kinetics and clearance of indium-111-labeled autologous platelets. *J Nucl Med* 30:629–637
18. Nimmerjahn F, Ravetch JV (2008) Fc gamma receptors as regulators of immune responses. *Nat Rev Immunol* 8:34–47
19. Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. *N Engl J Med* 346:995–1008
20. Carroll MC (2004) The complement system in regulation of adaptive immunity. *Nat Immunol* 5:981–986
21. Hogarth PM (2002) Fc receptors are major mediators of antibody based inflammation in autoimmunity. *Curr Opin Immunol* 14:798–802
22. Heyman B (2000) Regulation of antibody responses via antibodies, complement, and Fc receptors. *Annu Rev Immunol* 18:709–737
23. Nimmerjahn F, Ravetch JV (2006) Fcγ receptors: old friends and new family members. *Immunity* 24:19–28
24. Baudino L, Nimmerjahn F, da Silveira SA, Martínez-Soria E, Saito T, Carroll M, Ravetch JV, Verbeek JS, Izui S (2008) Differential contribution of three activating IgG Fc receptors (Fc

- gamma RI, FcγRIII, and Fc gamma RIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. *J Immunol* 180:1948–1953
25. Giorgini A, Brown HJ, Lock HR, Nimmerjahn F, Ravetch JV, Verbeek JS, Sacks SH, Robson MG (2008) Fc gamma RIII and Fc gamma RIV Are Indispensable for Acute Glomerular Inflammation Induced by Switch Variant Monoclonal Antibodies. *J Immunol* 181:8745–8752
 26. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF (2006) Antibody isotype-specific engagement of Fc gamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. *J Exp Med* 203:743–753
 27. Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, Schmidt RE, Sandor M, Capel PJ, Daeron M, van de Winkel JG, Verbeek JS (1996) Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. *Immunity* 5:181–188
 28. Meyer D, Schiller C, Westermann J, Izui S, Hazenbos WL, Verbeek JS, Schmidt RE, Gessner JE (1998) FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. *Blood* 92:3997–4002
 29. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. *Science* 310:1510–1512
 30. Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RHJ, de Winkel J, van Egmond M (2008) Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gamma RI and Fc gamma RIV. *J Immunol* 181:6829–6836
 31. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. *J Exp Med* 203:789–797
 32. Bolland S, Ravetch JV (1999) Inhibitory pathways triggered by ITIM-containing receptors. *Adv Immunol* 72:149–177
 33. Ravetch JV, Lanier LL (2000) Immune inhibitory receptors. *Science* 290:84–89
 34. Baerenwaldt A, Nimmerjahn F (2008) Immune regulation—Fc gamma RIIB—regulating the balance between protective and autoreactive immune responses. *Immunol Cell Biol* 86:482–484
 35. Schmidt RE, Gessner JE (2005) Fc receptors and their interaction with complement in autoimmunity. *Immunol Lett* 100:56–67
 36. Deng R, Balthasar JP (2007) Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. *Blood* 109:2470–2476
 37. Nieswandt B, Echtenacher B, Wachs FP, Schroder J, Gessner JE, Schmidt RE, Grau GE, Mannel DN (1999) Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. *Blood* 94:684–693
 38. Clynes R, Ravetch JV (1995) Cytotoxic antibodies trigger inflammation through Fc receptors. *Immunity* 3:21–26
 39. Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. *Science* 291:484–486
 40. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, Bleeker WK (2001) Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. *Blood* 98:1095–1099
 41. Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS, Isturiz MA (2000) Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. *Blood* 96:2834–2840
 42. Hirano M, Davis RS, Fine WD, Nakamura S, Shimizu K, Yagi H, Kato K, Stephan RP, Cooper MD (2007) IgE immune complexes activate macrophages through FcγRIII binding. *Nat Immunol* 8:762–771
 43. Clarkson SB, Bussell JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC (1986) Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. *N Engl J Med* 314:1236–1239
 44. Ericson SG, Coleman KD, Wardwell K, Baker S, Fanger MW, Guyre PM, Ely P (1996) Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. *Br J Haematol* 92:718–724
 45. Psaila B, Bussell JB (2008) Fc receptors in immune thrombocytopenias: a target for immunomodulation? *J Clin Invest* 118:2677–2681
 46. Wallace PK, Keler T, Guyre PM, Fanger MW (1997) Fc gamma RI blockade and modulation for immunotherapy. *Cancer Immunol Immunother* 45:137–141
 47. Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. *Annu Rev Immunol* 26:513–533
 48. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lunemann JD (2009) Impaired inhibitory FcγRIII expression on B cells in chronic inflammatory demyelinating polyneuropathy. *Proc Natl Acad Sci U S A* 106:4788–4792
 49. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. *Nat Rev Immunol* 5:953–964
 50. Mizutani H, Furubayashi T, Kashiwagi H, Honda S, Take H, Kurata Y, Yonezawa T, Tarui S, Ikehara S (1992) Effects of splenectomy on immune thrombocytopenic purpura in (NZW x BXSB) F1 mice: analyses of platelet kinetics and anti-platelet antibody production. *Thromb Haemost* 67:563–566
 51. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV (2005) FcγRIII: a novel FcR with distinct IgG subclass specificity. *Immunity* 23:41–51
 52. van Rooijen N, van Kesteren-Hendriks E (2002) Clodronate liposomes: perspectives in research and therapeutics. *J Liposome Res* 12:81–94
 53. McKenzie SE (2002) Humanized mouse models of FcR clearance in immune platelet disorders. *Blood Rev* 16:3–5